Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics, Inc. (KYMR)
:KYMR
KYMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.07 - $53.27
Previous CloseN/A
Volume48.51K
Average Volume (3M)674.01K
Market Cap
$2.11B
Enterprise Value$3.14B
Total Cash (Recent Filing)$120.26M
Total Debt (Recent Filing)$87.76M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
May 01, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.97
Shares Outstanding64,944,140
10 Day Avg. Volume645,405
30 Day Avg. Volume674,013
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)44.89
Price to Cash Flow (P/CF)-8.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit66.73
Enterprise Value/Ebitda-14.53
Forecast
1Y Price Target
$58.83Price Target Upside80.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Kymera Therapeutics News
PremiumCompany Announcements
Kymera Therapeutics Grants Performance Stock Units to Executives
PremiumCompany Announcements
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges---
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyKYMR seems to have covered their ground thoroughly with thousands of pages across the patents, underscoring their lead position in development of a STAT6 degrader.
Preclinical ResultsPreclinically, KYMR has demonstrated robust and selective degradation of STAT6 with oral dosing in large animal models.
Bears Say
Price Target AdjustmentRe-evaluation of opex assumptions in 2025 and beyond reduces the price target from $60 to $54.
Risk/Benefit ProfilesAnalyst's recommendation is cautious on the risk/benefit profiles of lead assets given the high bar for success.
---
Ownership Overview
28.27% Insiders
30.51% Mutual Funds
0.06% Other Institutional Investors
28.02% Public Companies and
Individual Investors
KYMR FAQ
What was Kymera Therapeutics, Inc.’s price range in the past 12 months?
Kymera Therapeutics, Inc. lowest stock price was $29.07 and its highest was $53.27 in the past 12 months.
What is Kymera Therapeutics, Inc.’s market cap?
Kymera Therapeutics, Inc.’s market cap is $2.11B.
When is Kymera Therapeutics, Inc.’s upcoming earnings report date?
Kymera Therapeutics, Inc.’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Kymera Therapeutics, Inc.’s earnings last quarter?
Kymera Therapeutics, Inc. released its earnings results on Feb 27, 2025. The company reported -$0.88 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$0.105.
Is Kymera Therapeutics, Inc. overvalued?
According to Wall Street analysts Kymera Therapeutics, Inc.’s price is currently Undervalued.
Does Kymera Therapeutics, Inc. pay dividends?
Kymera Therapeutics, Inc. does not currently pay dividends.
What is Kymera Therapeutics, Inc.’s EPS estimate?
Kymera Therapeutics, Inc.’s EPS estimate is -0.9.
How many shares outstanding does Kymera Therapeutics, Inc. have?
Kymera Therapeutics, Inc. has 64,944,140 shares outstanding.
What happened to Kymera Therapeutics, Inc.’s price movement after its last earnings report?
Kymera Therapeutics, Inc. reported an EPS of -$0.88 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went down -14.451%.
Which hedge fund is a major shareholder of Kymera Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYMR
---
Kymera Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.83 (80.79% Upside)
$58.83 (80.79% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 776.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $499.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.28%
12-Months-Change
Fundamentals
Return on Equity
-36.38%
Trailing 12-Months
Asset Growth
69.87%
Trailing 12-Months
Company Description
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
---
KYMR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant clinical progress and strategic initiatives, such as the advancement of STAT6 and TYK2 programs and the expansion of collaboration with Sanofi, which supports a positive outlook. However, increased operational costs and limited revenue diversification present challenges.Read More>---
KYMR Stock 12 Month Forecast
Average Price Target
$58.83
▲(80.79% Upside)
Technical Analysis
Bluebird Bio
―
Ultragenyx Pharmaceutical
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Arvinas Holding Company
―
Best Analysts Covering KYMR
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+37.67%
reiterated a buy rating 26 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +37.67% per trade.
---